{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2960.391","value":"9094.76"}]}],"title":"AUClast at Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3996.826","value":"9293.39"}]}],"title":"AUClast at Day 29"}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"AUClast at Days 1 and 29 was analyzed. AUClast is defined as the concentration of drug from time zero to the last observable concentration","dispersionType":"Standard Deviation","groups":[{"description":"Idelalisib 150 mg tablet administered orally twice daily until tumor progression or development of unacceptable toxicity.","id":"OG000","title":"Idelalisib"}],"paramType":"MEAN","populationDescription":"Participants in the PK Analysis Set with available data were analyzed.","reportingStatus":"POSTED","timeFrame":"Predose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hours postdose on Days 1 and 29","title":"PK Parameter: AUClast","type":"SECONDARY","unitOfMeasure":"hours x ng/mL"}